Idiopathic pulmonary fibrosis: the turning point is now!

Funke, Manuela; Geiser, Thomas (2015). Idiopathic pulmonary fibrosis: the turning point is now! Swiss medical weekly, 145, w14139. EMH Schweizerischer Ärzteverlag 10.4414/smw.2015.14139

[img]
Preview
Text
smw-2015-14139.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (1MB) | Preview

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with poor survival. Recent studies have improved understanding of IPF and new discoveries have led to novel treatment options, which now have become available for patients. In face of the newly available therapies we present an update on the pathophysiology and epidemiology of IPF. We discuss the typical clinical findings and elaborate diagnostic procedures according to current guidelines and our daily practice approach. The role of biomarkers will briefly be outlined. Finally, we discuss novel antifibrotic treatment options for IPF (pirfenidone, nintedanib) and the management of patients regarding to comorbidities and complications. Both pirfenidone and nintedanib were shown to reduce the progression of IPF and therefore represent novel therapeutic strategies in this so far untreatable chronic lung disease.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Pneumology

UniBE Contributor:

Funke, Manuela and Geiser, Thomas

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1424-7860

Publisher:

EMH Schweizerischer Ärzteverlag

Language:

English

Submitter:

Rahel Holderegger

Date Deposited:

06 Apr 2016 08:53

Last Modified:

07 Apr 2016 22:54

Publisher DOI:

10.4414/smw.2015.14139

PubMed ID:

26024356

BORIS DOI:

10.7892/boris.78846

URI:

https://boris.unibe.ch/id/eprint/78846

Actions (login required)

Edit item Edit item
Provide Feedback